The Michigan Senate recently passed a bill to repeal a
long-standing state law immunizing pharmaceutical manufacturers and
sellers from product liability suits where the pharmaceutical
products were approved by the U.S. Food and Drug Administration
("FDA").
If Senate Bill 410 is signed into law, Michigan could soon
become an active jurisdiction for product liability cases against
pharmaceutical companies and health care providers who distribute
their products.
Michigan's Product Liability Act currently provides an
absolute defense to the makers and sellers of FDA-approved
pharmaceuticals in product liability suits unless the FDA
determines that fraud or bribery influenced the approval process.
Senate Bill 410 eliminates this immunity provision, leaving
pharmaceutical manufacturers and sellers protected only by a
rebuttable presumption that a pharmaceutical product is not
defective if it conforms to the FDA's standards and regulations
while subject to the company's